Figure: Human pharmacokinetic results of Lipo-AB and AmBisome®
R-Mean: AmBisome®
T-Mean: Lipo-AB
Human pharmacokinetic results are similar to reference drug as shown as Figure.
Liposomal Amphotericin B for Injection is a liposomal form of amphotericin B used to treat fungal infections caused by Aspergillus, Candida and Cryptococcus. Due to the smaller size, higher transition temperature and more rigid bilayer of the liposome, it finally provides a persistent pool of liposomal Amphotericin B in plasma and a sustained delivery to the site of infection.
The in-vitro and in-vivo studies showthe similar drug release profile were obtained between Ambisome® and Lipo-AB.
TTY’s Lipo-AB provides the following advantages:
-
solid in-vitro and in-vivo data support
-
no patent infringement
-
compliance with cGMP
-
US CTD dossier available
|